Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

• Status: Recruiting
• Trial end date: 2024-05-01

Summary

this study aims to :

1. To compare the efficacy of combining low doses of Roxadustat Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase (PHD) inhibitor and iron versus standard treatment with erythropoietin-stimulating agents (ESA) in the treatment of anemia as a complication of chronic kidney disease (CKD) among dialysis-dependent patients.

2. To emphasize the safety profile of low doses of Roxadustat HIF-PHD.

3. To assess changes in the quality of life of patients with kidney disease before and after treatment.

• Phase: Phase 4

Details

• Lead Sponsor: Alexandria University
• Treatments: Enzyme Inhibitors